ZBIO
Zenas Biopharma Inc
$31.65
▼ 0.8%Updated Today 11:10 AM ET
ZBIO at a glance — five pillars scored 0–100 from real filed financials.
Overall: Unrated · 0/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
Market Cap
$0.00
P/E
—
Forward P/E (est.)
—
ROE
—
Revenue Growth
—
EPS Growth
—
Profit Margin
—
FCF Yield
—
Debt / Equity
—
ROIC
-93.0%
Interest Coverage
—
Current Ratio
9.93x
Dividend Yield
—
Implied Growth (rev. DCF)
—
Rating Score
0/100
Zenas Biopharma Inc (ZBIO) is a small-cap company in the Biotechnology industry, part of the Health Care sector of the S&P 500.
In its latest reported year it generated about $10.00M in revenue and posted a net loss of $377.74M.
Our model rates ZBIO Unrated (0/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
2Y CAGR
-55.3%
Revenue moved from $50.00M in 2023 to $10.00M in 2025, a -55.3% compound annual growth rate. The most recent year was roughly steady year over year. Slower, mature growth is common for established businesses.
Gross Margin
—
Operating Margin
-3830.6%
Net Margin
-3777.4%
ROE
—
Total Debt
$78.64M
Net Debt
-$117.94M
Net cash position
Net Debt / EBITDA
—
Debt / Equity
—
Leverage: debt-to-equity is n/a, with a current ratio of 9.9x. Detailed balance-sheet leverage is limited for this name. It carries roughly $78.64M of total debt against $196.58M of cash.
Operating CF
-$172.33M
Free Cash Flow
-$172.35M
FCF Margin
-1723.5%
In the latest year Zenas Biopharma Inc produced about -$172.33M of operating cash flow but negative free cash flow as it invested heavily. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
P/E
—
P/S
—
P/B
—
EV / EBITDA
—
ZBIO trades at n/a trailing earnings. With no positive trailing earnings, value it on sales, cash flow, or growth rather than P/E.
Where ZBIO sits versus its Health Care sector peers in the S&P 500.
Bands show the middle half (25th–75th percentile) of the 83 Health Care companies in the S&P 500 — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
How ZBIO stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (324 S&P 500 companies), ZBIO ranks #323 of 324 by our overall rating.
P/E vs sector
—
median 27.3x
ROE vs sector
—
median 14.1%
Growth vs sector
—
median 7.6%
Sector rank
#323
of 324 by rating
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 324 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$0.00 – $0.00
vs. $31.65 today · expected CAGR -70% – -66%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $10.80M | $11.66M | $12.60M | $13.60M | $14.69M |
| Net income | $324.00K | $349.92K | $377.91K | $408.15K | $440.80K |
| EPS | $0.00 | $0.01 | $0.01 | $0.01 | $0.01 |
| Share price (low) | $0.06 | $0.06 | $0.07 | $0.08 | $0.08 |
| Share price (high) | $0.10 | $0.11 | $0.12 | $0.13 | $0.14 |
| CAGR (low–high) | -100% / -100% | -95% / -94% | -87% / -85% | -78% / -75% | -70% / -66% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for ZBIO:
- As an established S&P 500 member in Health Care, it brings scale and a long operating history.
The case against ZBIO:
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: Zenas Biopharma Inc is a small-cap health care business growing at a mature pace, with modest profitability, and a heavier debt load to watch. It trades at n/a earnings, which our model scores Unrated (0/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Latest SEC Filings
ZBIO's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen.
ZBIO — frequently asked questions
Is ZBIO a good stock to buy?
We don't give buy or sell advice. Review Zenas Biopharma Inc's fundamentals, valuation, and 5-year financials on this page, then make your own decision — and consider a licensed professional.
Where does ZBIO's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Zenas Biopharma Inc's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for ZBIO calculated?
It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.
Is this ZBIO analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell ZBIO. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.